ChemicalBook CAS DataBase List 1256921-89-7

1256921-89-7

Name	6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)-
CAS	1256921-89-7
Molecular Formula	C24H24N2O2
Molecular Weight	372.46
MOL File	1256921-89-7.mol

Chemical Properties

Melting point	250-254 °C (decomp)
Boiling point	594.7±50.0 °C(Predicted)
density	1.38±0.1 g/cm3(Predicted)
form	Solid
pka	9.87±0.40(Predicted)
color	Off-white to light yellow

Hazard Information

Description

KNT-127 is a δ-Opioid receptor agonist.

Uses

KNT-127 is a potent δ-opioid receptor agonist that crosses the blood-brain barrier (BBB). KNT-127 is highly selective to the δ receptor, with Ki values of 0.16, 21.3 and 153 nM for δ, μ and κ receptors, respectively. KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens, and prefrontal cortex. KNT-127 has analgesic, antidepressant and antianxiety activities[1][2][3][4][5].

in vivo

KNT-127 (10 mg/kg; Subcutaneous injection; Single dose) exerts antidepressant effects through Akt-mTORC1-p70S6K signaling pathway in medial prefrontal cortex and ERK-mTORC1-p70S6K signaling pathway in amygdala^[1].
KNT-127 (20 mg/kg; Intraperitoneal injection; 38 days) has an improved effect in mouse models of depression^[2].
KNT-127 (5 mg/kg; Subcutaneous injection; Single dose) has an improved effect in mouse models of chronic migraine^[3].

Animal Model:	Chronic vicarious social defeat stress (cVSDS) treated male C57BL/6J mice^[2]
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection (i.p.); 38 days
Result:	Improved decreased social interaction behaviors and increased serum corticosterone levels. Suppressed decreases in the hippocampal newborn neuron survival rate. Inhibited cVSDS-induced overactivation of microglia.

Animal Model:	Nitroglycerin treated C57BL6/J mice^[3]
Dosage:	5 mg/kg
Administration:	Subcutaneous injection (s.c.); Single dose
Result:	Did not alter mechanical responses in vehicle pre-treated mice. Inhibited Nitroglycerin-induced chronic allodynia.

IC 50

δ Opioid Receptor/DOR; mTORC1

References

[1] Yoshioka T, et al. Delta opioid receptor agonists activate PI3K-mTORC1 signaling in parvalbumin-positive interneurons in mouse infralimbic prefrontal cortex to exert acute antidepressant-lie effects. Mol Psychiatry. 2024 Dec 6. DOI:10.1038/s41380-024-02814-z
[2] Yoshioka T, et al. KNT-127, a selective delta opioid receptor agonist, shows beneficial effects in the hippocampal dentate gyrus of a chronic vicarious social defeat stress mouse model. Neuropharmacology. 2023 Jul 1;232:109511. DOI:10.1016/j.neuropharm.2023.109511
[3] Bertels Z, et al. A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia. Headache. 2021 Jan;61(1):170-178. DOI:10.1111/head.14019
[4] Nagase H, et al. Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010;20(21):6302-6305. DOI:10.1016/j.bmcl.2010.08.083
[5] Tanahashi S, et al. Novel δ1-receptor agonist KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex. Neuropharmacology. 2012;62(5-6):2057-2067. DOI:10.1016/j.neuropharm.2012.01.005

Supplier

Send Inquriy